Details for New Drug Application (NDA): 205626
✉ Email this page to a colleague
NDA 205626 describes LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE, which is a drug marketed by Micro Labs and is included in one NDA. Additional details are available on the LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE profile page.
The generic ingredient in LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE is lamivudine; nevirapine; zidovudine. There are twenty-nine drug master file entries for this compound. Additional details are available on the lamivudine; nevirapine; zidovudine profile page.
The generic ingredient in LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE is lamivudine; nevirapine; zidovudine. There are twenty-nine drug master file entries for this compound. Additional details are available on the lamivudine; nevirapine; zidovudine profile page.
Summary for 205626
| Tradename: | LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE |
| Applicant: | Micro Labs |
| Ingredient: | lamivudine; nevirapine; zidovudine |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 150MG;200MG;300MG | ||||
| Approval Date: | Aug 13, 2018 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
